New pill joins fight against advanced liver cancer in major trial
Disease control
Not yet recruiting
This study aims to see if adding a new oral drug, TPST-1120, to the current standard treatment helps adults with advanced liver cancer live longer and keep their cancer from growing. About 740 participants will be randomly assigned to receive either the new three-drug combination…
Phase: PHASE3 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC